Morgan Stanley’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-336,931
| Closed | -$20.2M | – | 6920 |
|
|
2019
Q4 | $20.2M | Buy |
336,931
+152,758
| +83% | +$5.73M | ﹤0.01% | 1649 |
|
|
2019
Q3 | $5.17M | Buy |
184,173
+19,744
| +12% | +$674K | ﹤0.01% | 2841 |
|
|
2019
Q2 | $6.22M | Buy |
164,429
+155,945
| +1,838% | +$5.99M | ﹤0.01% | 2694 |
|
|
2019
Q1 | $331K | Sell |
8,484
-454,744
| -98% | -$13M | ﹤0.01% | 4793 |
|
|
2018
Q4 | $9.88M | Buy |
463,228
+334,423
| +260% | +$8.63M | ﹤0.01% | 2147 |
|
|
2018
Q3 | $5.1M | Sell |
128,805
-80,573
| -38% | -$3M | ﹤0.01% | 3159 |
|
|
2018
Q2 | $8M | Sell |
209,378
-44,281
| -17% | -$1.64M | ﹤0.01% | 2627 |
|
|
2018
Q1 | $7.62M | Buy |
253,659
+189,480
| +295% | +$6.41M | ﹤0.01% | 2610 |
|
|
2017
Q4 | $2M | Sell |
64,179
-86,471
| -57% | -$2.37M | ﹤0.01% | 4027 |
|
|
2017
Q3 | $4.22M | Buy |
150,650
+132,830
| +745% | +$2.88M | ﹤0.01% | 3151 |
|
|
2017
Q2 | $341K | Buy |
17,820
+8,696
| +95% | +$139K | ﹤0.01% | 5031 |
|
|
2017
Q1 | $156K | Sell |
9,124
-7,593
| -45% | -$123K | ﹤0.01% | 5425 |
|
|
2016
Q4 | $305K | Buy |
+16,717
| New | +$289K | ﹤0.01% | 5179 |
|
Morgan Stanley's BOLD Position: Q1 2020 in Review
Morgan Stanley sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 336,931 shares — an estimated $20.2M sold.
Morgan Stanley first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $20.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Morgan Stanley reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Morgan Stanley sold 336,931 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $20.2M.
- Morgan Stanley first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
- Morgan Stanley's Audentes Therapeutics, Inc position peaked at $20.2M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.